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Background: A variety of instruments have been used to assess outcomes for patients with venous leg
ulcers. This study sought to identify, evaluate and recommend the most appropriate patient-reported
outcome measures (PROMs) for English-speaking patients with venous leg ulcers.
Methods: This systematic review used a two-stage search approach. Electronic searches of major
databases including MEDLINE were completed in October 2015, and then updated in July 2016.
Additional studies were identified from citation checking. Study selection, data extraction and quality
assessment were undertaken independently by at least two reviewers. Evaluation and summary of mea-
surement properties of identified PROMs were done using standard and adapted study-relevant criteria.
Results: Ten studies with data for four generic PROMS and six condition-specific measures were
identified. No generic PROM showed adequate content and criterion validity; however, the EuroQoL
Five Dimensions (EQ-5D™), Nottingham Health Profile (NHP) and 12-item Short-Form Health Survey
(SF-12®) had good acceptability. In general, the EQ-5D™ showed poor responsiveness in patients with
venous leg ulcers. Most condition-specific PROMs demonstrated poor criterion and construct validity.
Overall, there was some evidence of internal consistency for the Venous Leg Ulcer Quality of Life
(VLU-QoL) and the Sheffield Preference-based Venous Ulcer questionnaire (SPVU-5D). Test–retest
reliability was satisfactory for the Venous Leg Ulcer Self-Efficacy Tool (VeLUSET).
Conclusion: The NHP and VLU-QoL questionnaire seemed the most suitable PROMs for use by
clinicians. However, a valid condition-specific PROM is still required.
Preliminary findings presented to a meeting of the Society of Academic and Research Surgery, Dublin, Ireland, January
2017; published in abstract form as Br J Surg 2017; 104(Suppl 3): 14
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Introduction
Venous leg ulcers (VLUs) are associated with considerable
morbidity and health costs1,2. They are the most common
kind of chronic leg ulcers; up to 70 per cent of such ulcers
are caused solely by venous disease3,4. Open unhealed
VLUs have estimated point prevalence ranging from 0⋅1 to
0⋅3 per cent in the UK5–7. They are common in the elderly
but relatively rare among patients aged less than 45 years7,8.
VLUs are commonly associated with a history of venous
insufficiency; they are thought to be caused by venous valve
incompetence and calf muscle pump insufficiency, both of
which lead to venous stasis and hypertension with resulting
localized tissue ischaemia8. The natural history of VLUs
consists of a continuous cycle of healing and recurrence.
Available evidence suggests that between 30 and 70 per cent
of VLUs heal by 6months, but an estimated 10–20 per cent
are treated for over a year9,10. Even so, there is high risk of
recurrence, with some studies reporting a recurrence rate
of 45 per cent11. Treatment of VLUs is usually associated
with high healthcare costs12. In the UK, estimated annual
expenditure based on 2005–2006 National Health Service
(NHS) data ranged between €245 and 287 million (or
€2175–2610 per patient) for treatment in the primary care
setting13.
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Healthcare expenditure, patient-reported outcome
measures (PROMs) and patient satisfaction are closely
related14. Indicators such as wound healing, recurrence,
readmission and adverse clinical events reveal little about
the health of the majority of patients. Conversely, PROMs
provide a more comprehensive and sensitive measure of
patients’ health15,16. These measures can be used as clinical
outcomes to optimize management strategies and also
examine the performance of healthcare providers.
The aim of this review was to identify, evaluate and rec-
ommend the most appropriate PROMs for use in clinical
practice among English-speaking patients with VLUs.
Methods
A systematic review was conducted based on a prespec-
ified protocol (http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42015024820) in line with
recommendations of the PRISMA statement17.
Literature searches
Electronic searches, without language or date restric-
tions, were undertaken systematically in MEDLINE, and
MEDLINE In-Process, Embase, the Cochrane Library,
CINAHL, PROQOLID PsycINFO and Web of Science.
A two-stage approach was used in theMEDLINE searches
and adapted for the remaining databases (Tables S1 and
S2, supporting information). The aim of the first search
(search 1) was to identify studies reporting PROMs in
patients with chronic venous disease of the leg. The next
stage (search 2) was designed to find studies validating the
measurement properties of relevant PROMs and any stud-
ies that had not been identified previously. The strategy for
stage 1 consisted of free-text words and Medical Subject
Heading (MeSH) terms for venous insufficiency, varicose
veins and VLUs as well as terms for known generic and
condition-specific PROMs, such as EuroQol Five Dimen-
sions (EQ-5D) andCharingCross VenousUlcerQuestion-
naire or CXVUQ. Additional terms for PROMs identified
from records retrieved during search 1, and a methodolog-
ical filter for finding studies on measurement properties
were included in the previously developed search strategy
to undertake search 2.
Electronic searches were undertaken from the date
of database inception up to October 2015; an updated
search in MEDLINE (including in-process and other
non-indexed citations) was completed in July 2016.
Supplementary searches included electronic searches
in PROQOLID, the PROMs Bibliography (Oxford
University) and Google Scholar; citation searching; and
checking of reference lists of included studies.
Study eligibility and selection
Studies were selected for inclusion in this review if they
assessed the psychometric properties of PROMs admin-
istered as English version questionnaires to patients aged
at least 18 years with VLUs. Based on current evidence
regarding issues with language and cultural adaptions and
translations of PROMs18, only PROMs administered as
original English questionnaires were considered eligible.
The following exclusion criteria were applied: studies based
on non-English or translated versions of non-English
PROMs; studies in patients with acute deep vein throm-
bosis, post-thrombotic syndrome, varicose veins, or leg
ulcers with arterial, mixed or unknown aetiology; and
review articles, abstracts, editorials or letters. Study selec-
tion was completed by one reviewer and checked by a sec-
ond reviewer. Disagreements were resolved by discussion
or referred to a third researcher if needed.
Data extraction
Data extracted were related to general information (name
of first author, year of publication, setting/country); study
type (PROMs development and validation study or clinical
study); population characteristics (sample size, demograph-
ics, type of VLU, treatment received); PROM-specific
details (name and type, development method, psycho-
metric evaluation and timing of assessments). Where there
were multiple publications of a single study, data were
extracted and presented as a single study. Data extraction
was completed by one reviewer and checked by a sec-
ond researcher. Discrepancies were checked, discussed and
resolved by consensus.
Methodological assessment of study quality
The methodological quality of the psychometric validation
studies was assessed using criteria adopted from the COS-
MIN checklist19,20, University of Oxford PROMs develop-
ment criteria and other studies21–28. These criteria were
compatible with the US Food and Drug Administration
PROMs guidelines (Table 1).
Study-specific criteria used to appraise reported psy-
chometric properties in this study have been used
effectively in related reviews29,30. Psychometric prop-
erties were summarized using the following ratings: 0,
not reported; –, evidence not in favour; +/–, conflict-
ing evidence; and +, evidence in favour. Disagreements
in psychometric evaluations and analysis were resolved
by discussion, and referred to a third researcher when
necessary.
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Table 1 Appraisal criteria for assessing the psychometric properties of patient-reported outcome measures
Psychometric
property domains Subdomain Thresholds
Reliability Test–retest reliability Intraclass correlation/weighted κ ≥0⋅70 for group comparisons
Intraclass correlation/weighted κ ≥0⋅90 for individual scores
Evidence of mean difference between time point 1 and time point 2, reported with 95 per cent c.i.
(using paired t test or Wilcoxon signed-rank test)21
Internal consistency Cronbach’s α score of ≥0⋅70 indicates good evidence, but the score should not exceed
≥0⋅92 for group comparison
Item total correlations should be ≥0⋅2023
Validity Content validity Evidence that the instrument has been developed by undertaking a literature review, consulting
patients, clinicians and other experts19,21,23,26,28
Construct validity Correlation coefficient of ≥0⋅60 indicates strong evidence
This should be supported by specific directional hypotheses and a previous estimation of strength
of correlation19,21–23,26,28
Criterion validity Justification for selection of standard should be adequate
Correlation between PROM and standard ≥0⋅7022
Responsiveness Responsiveness Statistically significant changes in score of an expected magnitude based on methods including t
tests, effect size, standardized response means, Guyatt’s responsiveness index or
responsiveness statistics19,21,26,27
Acceptability Floor/ceiling effects Evidence of floor effect: 15 per cent of respondents are achieving the lowest score on the
instrument19,22
Evidence of ceiling effect: 15 per cent of respondents are achieving the highest score on the
instrument19,22
Acceptability Completeness of data supplied ≥80 per cent24,27,28
PROM, patient-reported outcome measure.
Results
Identified studies
A total of 3870 records were retrieved from searches
(Fig. 1). Ten studies31–40 (reporting on 4 generic and 6
condition-specific PROMs) were included in the review
after detailed examination of 37 full-text articles.
Study characteristics
Characteristics of the included studies are presented
in Table 2. With the exception of one study from New
Zealand36, all were conducted in the UK. Studies were
published between 1999 and 2015. The mean or median
age of participants ranged from 66⋅6 to 76 years. Partic-
ipants included in the selected studies differed in terms
of clinical presentation and ongoing ulcer treatments.
Patients with a history of VLUs, chronic ulceration and
active disease were included in three studies33,37,39. Timing
of the PROMs administration also varied across studies.
One study37 reported PROMs data collection at baseline
only, whereas the majority reported data collection at
baseline and 3months33,35,36,39,40; fewer studies collected
PROMs data at 12months35,40.
Four studies32,34,38,39 described the development and
validation of the Sheffield Preference-based Venous
Ulcer-5D questionnaire (SPVU-5D)38, CXVUQ39,
Venous Leg Ulcer Self-Efficacy Tool (VeLUSET)32
and Venous Leg Ulcer Quality of Life (VLU-QoL)
questionnaire34. The remaining studies assessed exist-
ing measures: the Nottingham Health Profile (NHP)33,
EuroQol Five Dimensions (EQ-5D™; EuroQol Group,
Rotterdam, The Netherlands)35,36,40, Medical Outcomes
Study 36-item Short Form Health Survey (SF-36®;
Optum, Eden Prairie, Minnesota, USA)33,36,39,40, Medi-
cal Outcomes Study 12-item Short Form Health Survey
(SF-12®; Optum)35, Hyland leg and ulcer questionnaire35,
Venous Insufficiency Epidemiological and Economic
Study Quality of Life/Symptoms (VEINES QoL/Sym)31
and CXVUQ36. The focus of PROMs differed across
a number of condition-specific measures. The Hyland
questionnaire35 provides estimates of health-related
quality of life (HRQoL) in patients with open ulcers
only, whereas the VeLUSET is a self-efficacy ques-
tionnaire designed for use by patients aged 60 years
and over. Palfreyman37 also validated the newly devel-
oped SPVU-5D38, which is currently the only existing
condition-specific PROM with preference weights based
on the EQ-5D™ algorithm.
A summary of psychometric properties (Table 3) revealed
that none of the PROMs identified fulfilled all the psycho-
metric criteria. Existing condition-specific instruments
showed limitations in their applicability, either owing to
flaws in their validation or development. Furthermore,
the responsiveness of the generic instruments such as
© 2017 The Authors. www.bjsopen.com BJS Open 2017; 1: 138–147
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Fig. 1 PRISMA diagram selection of studies for review. PROM, patient-reported outcome measure
EQ-5D™ and SF-36® was either weak or did not support
their use in patients with VLUs.
Psychometric evidence for generic instruments
used in patients with venous leg ulcers
EuroQol Five Dimensions questionnaire
EQ-5D™ is a generic measure of HRQoL that consists
of five dimensions (mobility, self-care, ability to undertake
usual activities, pain, anxiety/depression) and a visual
analogue scale, derived from interviews with a sample of
3395 members of the UK public41. The responsiveness
and acceptability of this instrument were examined as part
of the HALT (Honey as Adjuvant Leg Ulcer Therapy)
trial36, VenUS I (Venous Ulcer Study I) study35 and also by
Walters and colleagues40. All three studies35,36,40 described
lack of responsiveness to change over specified follow-up
periods but reported acceptability (80 per cent completed
data). All evaluations were conducted within RCTs. Wal-
ters and colleagues40 also reported a good floor/ceiling
effect for this instrument.
Thirty-six-item Short Form Health Survey
The SF-36® questionnaire covers 36 questions divided
across eight dimensions: physical functioning, role lim-
itations because of physical health, social functioning,
vitality or energy, bodily pain, mental health, role lim-
itations because of emotional problems and general
health. The acceptability, internal consistency and con-
struct validity of this instrument were assessed as part
of a multicentre RCT40 comparing the effectiveness of
four-layer compression therapy versus usual care. The
instrument demonstrated good acceptability, with 86
per cent of participants completing questionnaires. The
Cronbach’s α value for internal consistency was less than
0⋅7, based on four of its dimensions. Overall, the instru-
ment failed to show a statistically significant effect size
© 2017 The Authors. www.bjsopen.com BJS Open 2017; 1: 138–147
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Table 2 Characteristics of included studies reporting validation of patient-reported outcome measures in patients with venous leg ulcers
Reference Type of study PROMs No. of participants
Age
(years)*
Men
(%) Treatment
Timing of PROMs
assessment
Bland et al.31 RCT VEINES QOL/Sym Chronic venous leg
ulcers (451)
68⋅6 50⋅7 Four-layer bandage
versus two-layer
hosiery
Baseline, 2weeks
and 4months
Brown et al.32 PDVS VeLUSET Healed or recurrent ulcer
of venous or mixed
aetiology (205)
74⋅1 47⋅8 Usual care Baseline and
4weeks
Franks and Moffatt33 Non-RCT NHP
SF-36®
Chronic venous leg
ulcers (383)
74† 36⋅6 Compression
bandaging
Baseline and
12weeks
Hareendran et al.34 PDVS VLU-QoL Active venous leg ulcers
(160)
72 31 Compression
bandaging
Baseline and
8weeks
Iglesias et al.35 RCT Hyland
questionnaire
SF-12®
EQ-5D™
Chronic venous leg
ulcers (387)
71⋅6 41 Four-layer bandage
versus short
stretch bandage
Baseline, 3, 6, 9
and 12months
Jull et al.36‡ RCT SF-36®
EQ-5D™
CXVUQ
Active venous leg ulcers
(368)
67⋅7 48⋅9 MHICAD with
compression
bandaging versus
usual care
Baseline and
12weeks
Palfreyman37 PDVS SPVU-5D Active and chronic
venous leg ulcers (152)
66⋅6 n.r. Usual care Baseline
Palfreyman et al.38 PDVS SPVU-5D Active and chronic
venous leg ulcers (19)
n.r. n.r. Usual care n.r.
Smith et al.39 PDVS SF-36®
CXVUQ
Active venous leg ulcers
(98)
76† 34 Usual care Baseline, 6 and
12weeks
Walters et al.40 RCT EQ-5D™
SF-36®
Active and chronic
venous leg ulcers (233)
75† 33⋅5 Four-layer
compression
versus usual care
Baseline, 12weeks
and 12months
*Values are mean, except †median. ‡Study from New Zealand; all other studies were carried out in the UK. PROM, patient-reported outcome measure;
VEINES-QOL/Sym, Venous Insufficiency Epidemiological and Economic Study Quality of Life/Symptoms; PDVS, PROMs development and
validation study; VeLUSET, Venous Leg Ulcer Self-Efficacy Tool; NHP, Nottingham Health Profile; SF-36®, 36-item Short Form Health Survey;
VLU-QoL, Venous Leg Ulcer Quality of Life questionnaire; SF-12®, 12-item Short Form Health Survey; EQ-5D™, EuroQol Five Dimensions
questionnaire; CXVUQ, Charing Cross Venous Ulcer Questionnaire, MHICAD, manuka honey-impregnated calcium alginate dressings; SPVU-5D,
Sheffield Preference-based Venous Ulcer-5D questionnaire; n.r., not reported.
in relation to the size of the VLU. As a result, the con-
struct validity of SF-36® was poor. Comparisons between
healed and non-healed VLUs at baseline and 12months’
follow-up did not show statistically significant differences
in responsiveness for all dimensions of the questionnaire40.
The psychometric properties of this instrument were also
examined as part of the HALT trial36 in New Zealand,
which compared the effectiveness of an active dressing
in addition to compression bandage compared with usual
care. SF-36® showed good acceptability (with 98 per cent
complete data) and adequate responsiveness in seven of the
eight dimensions at 12weeks’ follow-up.
Twelve-item Short-Form Health Survey
The suitability of this generic item for measurement
of HRQoL in patients with VLUs was examined in a
large multicentre pragmatic RCT (VenUS I)35 assess-
ing the effectiveness of two types of bandages. SF-12®
questionnaires were completed by 88 per cent of the 387
participants, representing good acceptability. The respon-
siveness of the SF-12® was examined by comparing scores
of the physical component summary (PCS) and mental
component summary (MCS) of this questionnaire at base-
line and up to 12months of follow-up. The effect size
was found to be statistically significant at 6 and 12months
for the MCS only; the change in PCS scores was not
significant regardless of whether VLUs healed or not35.
Nottingham Health Profile
The NHP is a 38-item questionnaire with binary answers
(yes or no) to questions grouped into six domains, namely
energy, bodily pain, emotional status, sleep, social iso-
lation and physical mobility. The NHP was validated
in 383 patients with VLU, and administered at baseline
and 12weeks33. More than one-third of the patients
experienced healing of ulcers by 12weeks. Responsiveness
was examined by comparing mean score changes after
12weeks of treatment, and considered the patients’ per-
ceived change in health which was rated as improved, worse
© 2017 The Authors. www.bjsopen.com BJS Open 2017; 1: 138–147
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Table 3 Summary of the psychometric properties of patient-reported outcome measures in patients with venous leg ulcers
Internal
consistency
Test–retest
reliability
Content
validity
Criterion
validity
Construct
validity Responsiveness
Floor/ ceiling
effect Acceptability
Generic PROMS
NHP
Franks and Moffatt33 +/– 0 0 0 + + – +
SF-12®
Iglesias et al.35 0 0 0 0 0 +/– 0 +
SF-36®
Walters et al.40 – 0 0 0 – – +
Jull et al.36 0 0 0 0 0 +/– 0 +
EQ-5D™
Walters et al. 40 0 0 0 0 0 – + +
Iglesias et al.35 0 0 0 0 0 – 0 +
Jull et al.36 0 0 0 0 0 – 0 +
Condition-specific PROMS
VeLUSET
Brown et al.32 +/– + + 0 0 0 0 –
VLU-QoL34
Hareendran et al.34 + + + + + +/– + +/–
Hyland questionnaire
Iglesias et al.35 0 0 0 0 +/– +/– 0 –
SPVU-5D
Palfreyman et al.38 0 0 + 0 0 0 0 0
Palfreyman37 +/– 0 + 0 0 0 0 0
VEINES-QOL/Sym
Bland et al.31 + +/– 0 +/– + + – +
CXVUQ
Smith et al.39 +/– +/– + + 0 + – –
Jull et al.36 0 0 0 0 0 + 0 +
Psychometric and operational criteria: 0, not reported (no evaluation completed); +/–, weak evidence; +, evidence in favour; –, evidence not in favour.
PROM, patient-reported outcome measure; NHP, Nottingham Health Profile; SF-12®, 12-item Short Form Health Survey; SF-36®, 36-item Short
Form Health Survey; EQ-5D™, EuroQol Five Dimensions questionnaire; VeLUSET, Venous Leg Ulcer Self-Efficacy Tool; VLU-QoL, Venous Leg
Ulcer Quality of Life questionnaire; SPVU-5D, Sheffield Preference-based Venous Ulcer-5D questionnaire; VEINES-QOL/Sym, Venous Insufficiency
Epidemiological and Economic Study Quality of Life/Symptoms; CXVUQ, Charing Cross Venous Ulcer Questionnaire.
or the same. NHP scores were analysed for patients with
or without healed ulcers over the study period. A paired t
test provided strong evidence that compression therapy led
to significant improvement in all dimensions of the NHP,
especially in patients with healed ulcers (mean difference
9⋅4; P= 0⋅004). The study reported evidence in support
of the acceptability of this instrument, with completion
rates for all domains ranging from 94 to 99 per cent. The
Cronbach’s α value was less than 0⋅7 when all items were
considered. However, most items in individual domains
had an α value of more than 0⋅7, with the exception of
energy and social isolation. The study33 provided evidence
in favour of construct validity of the NHP, showing a direct
relationship between larger ulcer sizes and longer ulcer
duration on the domain scores of the instrument. A high
floor effect (best health) was reported in the social isola-
tion, energy and emotional status domains, as the majority
of patients reported best possible health at baseline.
Psychometric evidence for the venous leg
ulcer-specific PROMs
Charing Cross Venous Ulcer Questionnaire
This 20-item questionnaire39 was developed by involving
patients and clinicians. The authors were able to reduce
the items that did not provide discriminatory value by
performing factor analysis and floor/ceiling effect analysis,
after administering the preliminary version. In total, 12
items were removed from the initial 32. The remaining
items demonstrated modest internal consistency with a
Cronbach’s α of 0⋅93, indicating the need for further item
reduction. The scores of the eight dimensions of SF-36®
were used to examine the criterion validity of this PROM.
The reported analysis showed strong correlation between
SF-36® scores and those of the CXVUQ (r2 > 0⋅84,
P< 0⋅001), indicating good criterion validity39. The
instrument’s responsiveness was further demonstrated by
good correlation between scores and clinical outcomes
in two studies36,39. Responsiveness of the CXVUQ was
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reported to be adequate in patients with healed ulcers at
6weeks (P= 0⋅022) and 12weeks (P= 0⋅005)39.
Hyland questionnaire
The 34-item Hyland leg ulcer questionnaire35 was devel-
oped for patients with any type of leg ulcer, and provides
estimates of HRQoL in patients with open ulcers only. It is
divided into three sets of evaluations: a visual scale relating
to the current progress of the leg ulcer; four single items
(leg ulcer pain, sleep discomfort caused by the leg ulcer,
time spent thinking about the ulcer and time spent helping
the ulcer heal); and 29 items about HRQoL related to the
presence of an open leg ulcer. This instrument was eval-
uated psychometrically in an English-speaking population
as part of the VenUS I trial35. Evidence was weak for its
responsiveness and criterion validity. The acceptability for
the PROMS was poor (64 per cent complete data).
Sheffield Preference-based Venous Ulcer-5D questionnaire
This is the only condition-specific preference-based mea-
sure of HRQoL for patients with VLUs. It has five dimen-
sions (pain, mobility, mood, smell and social activities) and
each dimension has three to five levels37,38. The dimen-
sions were developed based on in-depth patient inter-
views, focus groups and input from clinicians. Preference
weights were obtained from aUK population survey, which
generated values for 720 health states. The completed
instrument consisted of 16 questions about the impact of
living with VLUs, combined with two generic question-
naires (EQ-5D™42 and SF-6D®43). Validation data for
the SPVU-5D (152 patients, mean age 66⋅6 years; 32 per
cent with recently active ulcers, 36 per cent with ulcer
duration exceeding 12months, 80 per cent with previous
history of ulcer) provided evidence formodest internal con-
sistency (Cronbach’s α> 0⋅93)37. However, there was little
evidence about its performance in terms of responsiveness
and test–retest reliability.
Venous Insufficiency Epidemiological and Economic Study
Quality of Life/Symptoms
This 26-item questionnaire addresses the following
dimensions related to chronic venous disease of the leg:
symptoms (12 items), limitations in daily activity (9 items)
and psychological impact (5 items)31. A summary score,
VEINES-QOL, is obtained by summarizing scores across
25 items. The remaining item is not scored, but provides
information about when leg pain is worst during the
day. The VEINES-Sym is derived from a subset of the
VEINES-QOL25. The VEINES-QOL/Sym was vali-
dated as part of the VenUS IV trial31, which compared
two-layer hosiery and a four-layer bandage system44. The
VEINES-QOL/Sym demonstrated good acceptability
with 82⋅4 per cent of the questionnaires complete at base-
line. Good internal consistency was observed in favour
of this instrument, with a Cronbach’s α of 0⋅88 and 0⋅81
for the VEINES-QOL and VEINES-Sym respectively.
Acceptable construct and criterion validity, based on com-
parisons with the pain subscale of the SF-12® and clinical
measures, were also reported. It also showed moderate
responsiveness when outcomes were examined at 4months
in patients with healed ulcers31. However, test–retest
reliability evidence was weak (κ score 0⋅42–0⋅73).
Venous Leg Ulcer Quality of Life
Item generation for the VLU-QoL was based on focus
group and in-depth interviews with patients with VLUs
(36 patients, 24 women; age 46–91 years)34. Some 48 ques-
tions were generated and administered to 124 patients with
at least one chronic VLU. The 48-item VLU-QoL was
retested in a subgroup (n= 78, 62⋅9 per cent) of previous
respondents after 48–72 h. The t test and Mann–Whitney
test showed statistically significant correlation. Afterwards,
14 of the 48 questions were excluded because they either
showed a poor floor/ceiling effect (more than 60 per cent
of respondents choosing never or all the time) or had high
interitem correlation. The final version of the instrument
consisted of 34 items with three domains (activity limita-
tions, 12 items; psychological effects, 12 items; and symp-
tom distress, 10 items). The internal consistency of all
the domains was high (Cronbach’s α> 0⋅8)34. The study
also reported strong correlation with the SF-36® MCS
and PCS scores, as well as a strong correlation with clin-
ical and reported ulcer symptoms. This provided satis-
factory criterion and construct validity evidence for the
questionnaire. On the other hand, there was weak evi-
dence of the responsiveness and acceptability. The interval
between these instrument tests was, however, short (base-
line and 8weeks)34.
Venous Leg Ulcer Self-Efficacy Tool
The VeLUSET is a self-efficacy questionnaire designed
for patients aged 60 years and over32. A focus group study
was conducted to identify themes relevant to patients with
VLU. Six main themes related to 111 items were found.
Following further qualitative research with patients and
experts, items were further reduced to 60. The accept-
ability of the instrument in the validation phase was
poor, with only 41 per cent of the data complete32. The
evidence for internal consistency (Cronbach’s α= 0⋅93)
indicated that some of the items in the questionnaire could
be made redundant. The test–retest reliability showed a
strong positive relationship between test and retest scores
(r= 0⋅92, P< 0⋅001) at baseline and 4 weeks32.
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Discussion
With high recurrence rates and complex management
pathways6,45, the use of outcomes that can capture the
impact of chronic venous leg ulceration on the patient’s
quality of life is vital. PROMs can help achieve this goal
by examining the effectiveness of interventions, assessing
the progress of conditions, as well as contributing to shared
decision-making between patients and carers.
The appropriateness of a PROM is closely related to
its acceptability or practicality (linked to respondent and
investigator burden in data collection), reliability and valid-
ity. It is also important that valid PROMs are developed and
assessed in a specific population and context that represents
the settings in which they will be used. The scope of the
present review was to identify relevant PROMS for health
evaluation and decision-making within the UK NHS. As a
result, stricter eligibility criteria were applied in the present
study than in earlier reviews46–49.
In general, generic PROMs did not demonstrate sat-
isfactory responsiveness, including changes in clinical
condition, for patients with VLUs. Of particular note was
the lack of responsiveness of the EQ-5D™ and its inability
to detect change over time. This raises the question of
whether it is an appropriate tool when economic evalua-
tions are incorporated into clinical trials of interventions
for patients with VLU in the UK31,35,36,40. Despite rec-
ommending use of the EQ-5D™ for health technology
evaluation, the National Institute for Health and Care
Excellence (NICE)50 recognizes that it may not be appro-
priate for all conditions, and this review suggests caution
in relation to VLUs.
On the basis of the criteria applied, the most appropriate
generic and condition-specific PROMs were the NHP and
the VLU-QoL. The NHP was found to be responsive to
change over time. Although it did not have evidence of
test–retest reliability, it exhibited good construct validity.
It seems to be the most appropriate generic tool for use
in this population. One limitation of the NHP is that it is
not suitable for obtaining utility estimates for economic
evaluations because there is currently no existing algo-
rithm for mapping its scores to preference weights. The
most suitable condition-specific tool identified was the
VLU-QoL. This instrument had good content validity,
construct validity and criterion validity, as well as internal
consistency. Evidence for its responsiveness, however,
was weak, probably reflecting the short interval between
baseline assessment and follow-up (only 8weeks) in a
population with long-term chronic VLUs34.
All studies were conducted in the UK with the exception
of one originating fromNew Zealand36. The psychometric
criteria applied in the appraisal of PROMs were based on
internationally accepted guidelines20,21,23,24. This was nec-
essary because of the absence of an agreed assessment tool,
and also owing to the limitations of using a single checklist
to assess the psychometric properties of PROMs51,52.
The review aimed to identify the most suitable PROMs
for use by clinicians in patients with VLUs. Therefore,
only studies reporting on the development and validation
of a relevant PROMwere considered. To assess the clinical
effectiveness of PROMs and their impact on patient man-
agement, the selection criteria may have covered clinical
studies that were not specifically designed to assess mea-
surement properties. This could lead to ambiguous find-
ings because, without a priori hypothesis testing, lack of
responsiveness of a PROMmay stem from a poor choice of
PROM tool or may be due to lack of effectiveness. There-
fore, there was a trade-off between achieving robustness of
the review of measurement properties and limited evidence
about how the PROMs were tested in the clinical setting.
The narrow eligibility criteria applied in this review were
considered appropriate. However, this led to the exclu-
sion of potentially relevant validation studies, for example
the Turkish version53 and Norwegian version54 of the
VEINES-QOL/Sym in patients with chronic venous insuf-
ficiency. Another limitation relates to the date of the last
literature search; it is possible that more recent studies may
not be included in this review. The heterogeneity in the
studymethodology, patient population and treatment path-
way could have potentially influenced the results. There
was also no explanation provided of how missing data were
dealt with in any of the included studies.
Requirements for a PROM for routine clinical practice
may differ from the requirements of outcome measures
to generate utility values for cost-effectiveness calcu-
lations. The VLU-QoL34 needs further evaluation to
assess its responsiveness. Further research to validate the
SPVU-5D38, the only preference-based condition-specific
questionnaire, is needed. This instrument seems a promis-
ing alternative to current generic preference-based
PROMs and can provide meaningful utility measures
for economic evaluations. Standardization in the conduct
and reporting of validation studies to facilitate meaningful
interpretation, comparison and analysis of data is still
needed.
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Internal
consistency
Test–retest
reliability
Content
validity
Criterion
Validity
Construct
validity Responsiveness
Floor/ ceiling
effect Acceptability
Generic PROMS
NHP
Franks and Moffatt33 +/– 0 0 0 + + – +
SF-12®
Iglesias et al.35 0 0 0 0 0 +/– 0 +
SF-36®
Walters et al. 940 – 0 0 0 – – +
Jull et al.36 0 0 0 0 0 +/– 0 +
EQ-5D™
Walters et al. 40 0 0 0 0 0 – + +
Iglesias et al.35 0 0 0 0 0 – 0 +
Jull et al.36 0 0 0 0 0 – 0 +
VeLUSET
Brown et al.32 +/– + + 0 0 0 0 –
VLU-QoL34
Hareendran et al.34 + + + + + +/– + –
Hyland questionnaire
Iglesias et al.35 0 0 0 0 +/– +/– 0 –
SPVU-5D
Palfreyman et al.38 0 0 + 0 0 0 0 0
Palfreyman37 +/– 0 + 0 0 0 0 0
VEINES-QOL/Sym
Bland et al.31 + +/– 0 +/– + + – +
CXVUQ
Smith et al.39 +/– +/– + + 0 + – –
Jull et al.36 0 0 0 0 0 + 0 +
The aim of the current review was to identify, evaluate and recommend the most appropriate patient-reported outcome measures
(PROMs) for English-speaking patients with venous leg ulcers (VLUs) in clinical practice. The Nottingham Health Profile (NHP)
and Venous Leg Ulcer Quality of Life (VLU-QOL) are considered to be the most suitable PROMs for use.
